IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 67.00
Bid: 66.00
Ask: 68.00
Change: 8.25 (14.04%)
Spread: 2.00 (3.03%)
Open: 59.50
High: 67.75
Low: 62.00
Prev. Close: 58.75
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta signs Covid sewage test deal with Integumen

Mon, 13th Jul 2020 09:18

(Sharecast News) - Biotherapeutics company Avacta Group has entered into a collaboration with its AIM peer Integumen, it announced on Monday, to evaluate recently-generated Affimer reagents that bind the SARS-CoV-2 spike protein for the detection of the coronavirus in wastewater, to provide a real-time alert system to warn of localised Covid-19 outbreaks.

The firm said more than 60% of Covid-19 positive patients had gastrointestinal symptoms, such as diarrhoea, nausea and vomiting, with the SARS-CoV-2 virus found in their faecal samples.

Sampling wastewater from households could thus provide an early warning system for localised outbreaks in communities.

Recently, Avacta said it had generated a number of highly-specific Affimer reagents that detected the SARS-C0V-2 virus spike protein, for use in diagnostic tests and in neutralising therapies.

The board aid the collaboration with Integumen aimed to evaluate some of those Affimer reagents in "next-generation" sensors, based on the real-time bacteria detection and alert system developed by Rinocloud - a subsidiary of Integumen - with the aim of integrating those sensors into Modern Water's Microtox water contamination system to detect the coronavirus.

Avacta said the Microtox system, which can detect the presence of contaminating bacteria, virus and toxins, was distributed by the AIM-traded Modern Water, with more than 3,000 installations globally.

The proposed Affimer sensors would be consumable items, to be replaced on a roughly monthly basis.

Once initial testing of the Affimer reagents was completed in the coming weeks, validation of the sensors would be carried out using SARS-CoV-2 virus samples in a containment level 3 laboratory at the University of Aberdeen.

Upon successful completion of the evaluation, Integumen and Avacta would enter into a supply agreement to allow Integumen to manufacture and commercialise the waste water detection sensors globally, by retrofitting into Microtox systems.

"I am very pleased to be entering into this collaboration with Integumen, which holds substantial commercial potential for an Affimer-based consumable SARS-CoV-2 detector unit to retrofit into the globally-installed base of Microtox systems," said Avacta chief executive officer Dr Alastair Smith.

"Affimer reagents are ideal for applications such as this, not only because of their sensitivity and specificity, but also because of their robustness, which is essential when being deployed in real-world situations, such as real-time waste water analysis."

Dr Smith said that with the spread of Covid-19 continuing to accelerate globally, the collaboration had the potential to deliver a product that would play a crucial role in the early detection of Covid-19 hotspots around the world.

"I look forward to updating the market very soon on progress with Integumen and our other Covid-19 related programmes."

Gerard Brandon, CEO of Integumen and chairman of Modern Water, added that the companies were "delighted" to be collaborating with Avacta, adding their "highly specific and robust" Affimer reagents to its "real-time alert arsenal" of pathogen-capture devices for the Covid-19 virus in sewage.

"The global pandemic has highlighted waste water as a potential early warning hotspot detection opportunity and the inclusion of Affimer reagents adds an established method of capturing the virus to a widely used pathogen alert system."

At 0916 BST, shares in Avacta Group were down 2.01% at 117.1p, while those in Integumen were up 10.53% at 2.1p and Modern Water was ahead 16.05% at 2.15p.
More News
10 Aug 2016 09:28

Avacta collaboration programme gets £3.8m grant

(ShareCast News) - A collaboration programme between AIM-listed Avacta and Leeds University has been awarded a £3.8m grant by the Medical Research Council. The biotherapeutics and research reagents developer said the grant was to develop novel, rapid diagnostic tools incorporating Affimer reagents,

Read more
10 Aug 2016 07:43

Avacta-Leeds University Partnership Gets GBP3.8 Million Grant

Read more
3 Aug 2016 15:02

Avacta granted European patent for Affimer technology

(ShareCast News) - European and US regulators handed down further patent decisions in favour of Avacta´s Affimer biotherapeutics and research reagents, helping the company to consolidate its intelectual property portfolio. In Europe, authorities granted the Life Sciences group the main patent for it

Read more
1 Aug 2016 14:16

Avacta revenue in line with forecasts, but losses mount

(ShareCast News) - Life sciences company Avacta said on Monday that revenue for the year to the end of July grew by around 19% but losses nearly doubled due to a change in accounting policy. In a pre-close trading update ahead of its preliminary results for the year to the end of July, Avacta said r

Read more
14 Jul 2016 08:34

Avacta Collaborating With Glythera To Develop Antibody Drugs

Read more
22 Jun 2016 10:54

Avacta claims development could lead to early Zika diagnosis

(ShareCast News) - Avacta, biotherapeutics and research agent developer, reported on Wednesday it had identified three proteins which could be used to develop the first tests to diagnose early stages of the Zika virus. Avacta said it found three 'Affimer' proteins capable of binding to a form of sec

Read more
22 Jun 2016 06:37

Avacta Identifies Affimer Proteins For Possible Zika Virus Tests

Read more
13 Jun 2016 08:23

Avacta Forms Partnership With Mologic To Develop Point-Of-Care Tests

Read more
29 Apr 2016 14:37

DIRECTOR DEALINGS: Avacta Chief Operating Officer Buys Shares

Read more
25 Apr 2016 08:22

Avacta Making Good Progress On Programmes As Interim Loss Widens

Read more
19 Apr 2016 09:27

Avacta Group Hails Milestone In Multi-Affimer Production

Read more
18 Apr 2016 15:05

Earnings, Trading Statements Calendar - Week Ahead

Read more
7 Mar 2016 15:39

Avacta appoints scientific advisory board

(ShareCast News) - Avacta Group established what it saw as one of the last pieces in the management puzzle to get its products towards the market, appointing professors Terence Rabbitts, Paul Moss and Adrian Hayday to form the company's scientific advisory board on Monday. The AIM-traded developer o

Read more
24 Feb 2016 08:56

Avacta Gets Grant For Work To Help Reduce Use Of Animal Testing

Read more
25 Jan 2016 10:36

Avacta Poaches Abcam's Cotrel For Chief Commercial Officer Role

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.